Investment Rating - The report maintains an OUTPERFORM rating for CSPC Pharmaceutical Group with a target price of HKD 5.97, indicating an expected upside from the current price of HKD 4.89 [2]. Core Insights - In FY24, the company achieved revenue of CNY 29.01 billion, a year-on-year increase of 1.7%, with finished drug revenue declining by 7.4% to CNY 23.74 billion due to volume-based procurement (VBP) impacts [3][12]. - The gross profit margin (GPM) was reported at 70.0%, a slight decrease of 0.5 percentage points year-on-year, while net profit attributable to shareholders fell by 26.3% to CNY 4.33 billion [3][12]. - The company is expected to see incremental revenue from innovative drug products exceeding CNY 1.5 billion in FY25, despite challenges in the oncology segment due to price cuts from VBP [4][13]. Financial Performance Summary - Revenue for FY24 was CNY 29.01 billion, with a breakdown showing finished drug sales at CNY 23.74 billion and API and functional food sales at CNY 5.27 billion [3][12]. - R&D expenses increased by 7.5% year-on-year to CNY 5.19 billion, representing 17.9% of total revenue [3][12]. - The company anticipates revenue growth in FY25, with total revenue projected at CNY 31.4 billion, reflecting an 8.2% year-on-year increase [7][17]. Segment Performance - The nervous system segment showed steady growth with sales reaching CNY 9.6 billion, a 6.1% increase year-on-year, driven by the performance of NBP [4][19]. - The oncology segment experienced a significant decline, with sales dropping to CNY 4.4 billion, a decrease of 28.3% year-on-year, primarily due to VBP impacts [4][19]. - The anti-infectives segment reported sales of CNY 4.1 billion, down 3.5% year-on-year, while the cardiovascular segment saw a decline of 14.8% to CNY 2.1 billion [4][19]. Licensing and Future Prospects - CSPC initiated a Phase III clinical trial for SYS6010 (EGFR ADC) in March 2025, with expectations for multiple out-licensing deals in 2025 [6][15]. - The company out-licensed ROR1 ADC to Radiance Biopharma, receiving an upfront payment of USD 15 million, with potential milestone payments of up to USD 1.2 billion [6][16]. - Licensing revenue is anticipated to become a recurring income stream for CSPC as it continues to expand its product offerings [6][16].

Investment Rating - The report maintains an "OUTPERFORM" rating for Morimatsu International Holdings with a target price of HKD 6.96, reflecting a potential upside from the current price of HKD 4.67 [2][20]. Core Insights - The company's FY24 revenue was CNY 6.95 billion, a decrease of 5.6% year-on-year, primarily due to delays in project execution. However, the gross profit margin improved to 29.5%, up 1.6 percentage points year-on-year, attributed to better operational efficiency and material cost control [3][4][16]. - The net profit attributable to shareholders was CNY 737 million, down 12.7% year-on-year, mainly impacted by accounts receivable impairment [17][20]. Revenue Breakdown - Revenue from Mainland China was CNY 2.75 billion, down 29.2% year-on-year, while overseas revenue reached CNY 4.20 billion, an increase of 20.8% year-on-year. Notably, North America saw a significant growth of 60.2% year-on-year [3][16]. - By segment, the oil and gas sector generated CNY 630 million (-35.2% y-y), while the power battery segment reported CNY 1.22 billion (+6.5% y-y) [22]. Order Backlogs - As of the end of FY24, the company had a backlog of CNY 8.1 billion, down from CNY 8.8 billion in the first half of 2024. The pharmaceutical sector accounted for CNY 2.3 billion of this backlog [5][18]. - New orders for FY24 totaled CNY 6.0 billion, with a notable decline of 11.3% in the second half of the year [5][18]. Valuation Adjustments - Due to weak backlog growth, revenue forecasts for FY25 and FY26 have been revised down to CNY 7.77 billion and CNY 8.47 billion, respectively, indicating growth rates of 11.8% and 9.1% year-on-year [8][20]. - The net profit forecasts for FY25 and FY26 have also been adjusted to CNY 872 million and CNY 939 million, suggesting growth rates of 18.3% and 7.7% year-on-year [8][20].

业绩同比高增，成本控制优异 周期/金属及材料 公司发布 2024 年业绩：2024 年实现营业收入 118.7 亿元，同比+12.7%；实现 归母净利润 7.0 亿元，同比+119.4%；24H2 实现营业收入 75.9 亿元，同比/环 比分别 +61.5%/+77.3% ，实现归母净利润 5.5 亿元，同比 / 环比分别 +175.0%/+260.3%。 财务数据与估值 证券研究报告 | 公司点评报告 2025 年 04 月 08 日 灵宝黄金（03330.HK） | 会计年度 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 10535 | 11867 | 14979 | 15984 | 17324 | | 同比增长 | 4% | 13% | 26% | 7% | 8% | | 营业利润(百万元) | 590 | 1022 | 1639 | 2265 | 2837 | | 同比增长 | 31% | 73% | 60% | 38% | 25% | | 归母净利润(百万元) ...

Investment Rating - The report maintains an "OUTPERFORM" rating for the company [2][11]. Core Insights - The company's core product sales are strong, with commercial sales revenue reaching RMB 2.00 billion, a 24.9% increase, while total revenue for 2024 was RMB 2.13 billion, reflecting a 53.1% decline primarily due to reduced licensing revenue [3][16]. - The company has effectively managed costs, resulting in a significant reduction in expense ratios across the board, with R&D expenses decreasing by 5.3% due to the transition of some outsourced clinical research services to in-house execution [4][18]. - The clinical pipeline is advancing steadily, with key programs such as Cadonilimab and Ivonescimab making progress in various trials, including those for hepatocellular carcinoma and non-small cell lung cancer [5][19][20]. Financial Performance - The company reported a net loss of RMB 501 million for 2024, but the operating net loss narrowed by 16.7% year-over-year to RMB 660 million [3][16]. - Revenue projections for 2025-2027 are set at RMB 3.41 billion, RMB 5.45 billion, and RMB 7.31 billion, respectively, with expected year-over-year growth rates of 60% and 34% in the following years [11][34]. - The company is expected to turn a profit in 2025, achieving a net profit of RMB 50 million [11][34]. Clinical Pipeline - Cadonilimab is involved in multiple clinical trials, including adjuvant treatment for hepatocellular carcinoma and combination therapies for non-small cell lung cancer [5][19]. - Ivonescimab is also progressing in various trials, including those for biliary tract cancer and head and neck squamous cell carcinoma [20][23]. - The company is expanding into antibody-drug conjugates (ADCs) with several candidates entering clinical or IND application stages [10][30][31]. Valuation and Target Price - The target price has been adjusted to HKD 96.6 per share, based on a DCF model with a WACC of 10.0% and a perpetual growth rate of 3.0% [11][34].

证券研究报告 美丽田园医疗健康 (2373 HK) 24 年业绩彰显强韧性 | 华泰研究 | | | 更新报告 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 08 日│中国香港 | 零售 | 2024 年公司营收 25.72 亿/yoy+19.9%，归母净利润 2.28 亿/yoy+5.9%。归 母净利率 8.9%/yoy-1.2pct，经调整净利润 2.52 亿/yoy+4.6%。2H24 奈瑞 儿正式并表，贡献收入 2.87 亿/利润 0.2 亿。内生方面，公司业务基石美容 与保健业务强韧性，医美客户渗透率持续提升，亚健康医疗服务板块快速放 量。外延方面，奈瑞儿 24 年已贡献业绩增量，后续公司有望凭借自身优势 持续整合市场提份额。宣派末期股息 1.13 亿，对应分红率 50%，并宣布未 来 3 年除特殊情况外分红率将不低于 50%。未来将引入长期战略投资者构 建健康多元股东生态体系。展望长期，公司仍有望持续积累优质客户，并通 过三美业务矩阵深度挖潜用户价值。维持"买入"评级。 美容与保健服务基本盘发展良好，亚健康医疗服务增速亮眼 24 年美容与保健服务营收 1 ...

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is expected to see a recovery in its core business of atomization, with promising growth in the HNB (Heated Not Burned) segment. The revenue growth trend is anticipated to continue into 2025, supported by increased demand for compliant products due to regulatory changes in the US and Europe [1][2][4] Summary by Sections Financial Performance - The company forecasts a pre-tax profit of 255 million RMB for Q1 2025, representing a year-over-year decline of 36.3%, and a post-tax profit of 192 million RMB, down 43.4% year-over-year. This decline is attributed to increased business investments and a higher tax rate [1] - For 2025, the company expects revenues to reach 12.96 billion RMB, reflecting a growth of 9.82% compared to 2024 [6] Business Segments - In the To B (business-to-business) segment, the company anticipates revenue recovery driven by stricter enforcement of regulations on non-compliant electronic vapor products in the US and increased demand for compliant products in Europe. Revenue growth in the US and Europe is projected at 5.2% and 14.4% respectively for the second half of 2024 [2] - The To C (business-to-consumer) segment is expected to see continued strong performance from the company's proprietary brand, VAPORESSO, with projected revenue of 2.48 billion RMB in 2024, a year-over-year increase of 34.0% [2] HNB Business - The company has made significant progress with its HNB business, particularly with the launch of new products by a major client, British American Tobacco (BAT). The Glo Hilo series is expected to be introduced to additional markets in 2025-2026, indicating substantial growth potential for the company [3] - The global HNB market was valued at 34.463 billion USD in 2023, with PMI holding a market share of 71% and BAT at 15.3%, highlighting the competitive landscape and growth opportunities for the company [3] Profit Forecast and Valuation - The report adjusts the profit forecasts for 2025-2027, estimating net profits of 1.323 billion RMB, 2.140 billion RMB, and 2.762 billion RMB respectively. The corresponding EPS is projected to be 0.21 RMB for 2025, 0.35 RMB for 2026, and 0.45 RMB for 2027 [4][6] - The target price is set at 16.25 HKD, based on a PE ratio of 43 times the expected EPS of 0.36 RMB for 2026 [4]

Investment Rating - The report maintains a "Buy" rating for Gushengtang (2273 HK) with a target price of HK$61.84, indicating a potential upside of +117% from the current price of HK$28.55 [3][9][19]. Core Insights - Gushengtang has shown robust growth in its healthcare solutions, with total revenue for 2024 reaching RMB 3.022 billion, a year-on-year increase of 30.1%, and net profit of RMB 307 million, up 21.4% [7][13]. - The company is expanding its international presence, having entered the Singapore market, which contributed RMB 31.52 million to its revenue [8]. - The report projects revenue and net profit growth rates for 2025E-2027E at 26%/23%/19% and 26%/24%/18%, respectively [7][15]. Financial Summary - Revenue for 2025E is projected at RMB 3.819 billion, with a gross profit of RMB 1.150 billion and a net profit of RMB 386 million [13][24]. - The earnings per share (EPS) for 2025E is estimated at RMB 1.61, with a P/E ratio of 16.1, which is lower than the industry average of 27x [3][19][21]. - The company’s gross margin is expected to remain stable at around 30% to 31% through 2027E [8][19]. Adjustments and Forecasts - The target price has been adjusted down from HK$73.95 to HK$61.84, reflecting a 16% decrease due to revised earnings forecasts [3][19]. - The report has lowered the 2025E and 2026E EPS estimates by 19% and 24%, respectively, due to anticipated costs associated with digital transformation and expansion efforts [15][17]. Valuation - The DCF valuation method indicates a target price of HK$61.84, corresponding to a P/E of 35x for 2025, suggesting a premium valuation due to the company's unique position in the TCM service market [19][20].

证券研究报告 永达汽车 (3669 HK) 传统品牌销量承压，新能源渠道扩张 提速 24 年新车销量承压，全年销售量 17.1 万辆，同比-12%，对应销售及相关 服务收入 494 亿元，同比-16%。得益于小米 SU7、问界 M9 等爆款热销， 新能源品牌销售表现亮眼，24 年收入 30 亿元，同比+85%，销售占比由 3% 提升至 6%；单车平均售价（直销+经销）同比提升 4 万元至 28 万元。新能 源相关的售后业务也同比提升，24 年独立新能源品牌维修收入 3 亿元，同 比+95%。二手车销售和整体售后服务业务收入分别为 97/38 亿元，同比 -28.4%/-0.1%。整体来看，24 年销售业务虽然承压，但我们看到新能源汽 车业务带来改善机会，为前后双端注入新动力。 优化门店结构+推进控本降费，应对盈利承压挑战 24 年公司毛利率为 8.3%，同比-0.7pct。其中新车销售及相关服务毛利率同 比-1.8pct 至 1.7%，主要系行业竞争加剧，新车市场价格下行造成压制；二 手车、售后、汽车经营租赁服务毛利率分别为 6.4%/42.2%/15.2%，同比 -0.9/-0.3/-7.6pct。面对利润 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is steadily advancing its various businesses and continuously expanding its cigarette export operations [4] - The company has signed a framework agreement with a subsequent contracting party, Mongkun Company, to expand its cigarette export business [4] - The company has applied for and received approval from the Stock Exchange to amend existing exemptions to cover the framework agreement with the subsequent contracting party [4] Business Performance - The cigarette export business is one of the company's main operations, achieving a volume of 3,339.7 million cigarettes in 2024, a year-on-year increase of 19.1% [5] - The revenue from cigarette exports reached 1,573.6 million HKD in 2024, up 30.2% year-on-year, accounting for 12% of total revenue [5] - The gross profit from cigarette exports was 277.4 million HKD, reflecting a 69.1% year-on-year increase and representing 20% of total gross profit [5] - The growth in the company's cigarette business is attributed to expanding operational regions, enhancing tax-inclusive business, and optimizing product mix [5] Financial Projections - The company is expected to generate total revenues of 143.96 billion HKD, 156.48 billion HKD, and 169.00 billion HKD for the years 2025, 2026, and 2027 respectively, with year-on-year growth rates of 10%, 9%, and 8% [6] - The projected net profit attributable to the parent company is 9.39 billion HKD, 10.44 billion HKD, and 11.71 billion HKD for the years 2025, 2026, and 2027 respectively, with growth rates of 10%, 11%, and 12% [6] - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 1.36 HKD, 1.51 HKD, and 1.69 HKD respectively, with corresponding price-to-earnings (P/E) ratios of 14.74, 13.26, and 11.82 [6] Key Financial Metrics - The company's total revenue for 2024 was 13,074 million HKD, with a year-on-year growth of 10% [9] - The return on equity (ROE) is projected to decrease from 28.41% in 2024 to 19.01% by 2027 [11] - The company's net profit margin is expected to remain stable, with a projected net profit margin of 6.53% for 2025 [11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is steadily advancing its various businesses and continuously expanding its cigarette export operations [4] - The company has signed a framework agreement with a subsequent contracting party, Mongkun Company, under the same terms as the original agreement [4] - The company has applied for and received approval from the Stock Exchange to amend existing exemptions to cover the framework agreement with subsequent contracting parties [4] Business Performance - The cigarette export business is one of the company's main operations, achieving a volume of 3,339.7 million cigarettes in 2024, a year-on-year increase of 19.1% [5] - The revenue from cigarette exports reached 1,573.6 million HKD in 2024, up 30.2% year-on-year, accounting for 12% of total revenue [5] - The gross profit from cigarette exports was 277.4 million HKD, reflecting a 69.1% year-on-year increase and representing 20% of total gross profit [5] - The growth in the company's cigarette business is attributed to expanding operational areas, introducing new products, and optimizing the product mix [5] Financial Projections - The company is expected to generate total revenue of 143.96 billion HKD, 156.48 billion HKD, and 169.00 billion HKD for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 10%, 9%, and 8% [6] - The projected net profit attributable to the parent company for the same years is 9.39 billion HKD, 10.44 billion HKD, and 11.71 billion HKD, with growth rates of 10%, 11%, and 12% [6] - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 1.36 HKD, 1.51 HKD, and 1.69 HKD, respectively, with corresponding price-to-earnings (P/E) ratios of 14.74, 13.26, and 11.82 [6] Key Financial Metrics - The company reported total revenue of 13,074 million HKD in 2024, with a year-on-year growth of 10% [9] - The return on equity (ROE) is projected to decrease from 28.41% in 2024 to 19.01% in 2027 [11] - The company’s total assets are expected to grow from 9,817 million HKD in 2024 to 13,524 million HKD in 2027 [11]